Our data suggested therefore that the rs1024611 SNP of CCL2 may configure as a genetic biomarker: (i) for the identification of ET and PV patients at higher risk of progression toward a spent phase; (ii) of adverse hematological presentation in MF patients [101]. Here, CCL2 is linked to essential thrombocythemia.